Last reviewed · How we verify

Lecanemab SC — Competitive Intelligence Brief

Lecanemab SC (Lecanemab SC) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (anti-amyloid-beta). Area: Neurology.

phase 3 Monoclonal antibody (anti-amyloid-beta) Amyloid-beta protofibrils Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Lecanemab SC (Lecanemab SC) — Eisai Inc.. Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lecanemab SC TARGET Lecanemab SC Eisai Inc. phase 3 Monoclonal antibody (anti-amyloid-beta) Amyloid-beta protofibrils
Lecanemab IV Lecanemab IV Eisai Inc. phase 3 Monoclonal antibody (anti-amyloid-beta) Amyloid-beta protofibrils
ABP 692 ABP 692 Amgen phase 3 Monoclonal antibody (anti-amyloid-beta) Amyloid-beta protofibrils

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (anti-amyloid-beta) class)

  1. Eisai Inc. · 2 drugs in this class
  2. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lecanemab SC — Competitive Intelligence Brief. https://druglandscape.com/ci/lecanemab-sc. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: